Nevirapine

Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.2. Antiretrovirals > 6.4.2.2. Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

EMLc | Codes ATC: J05AG01

Indication	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified Code ICD11: 1C62.Z
INN	Nevirapine
Type de médicament	Chemical agent
Type de liste	Liste de base
Formulations	**Oral > Liquid:** 50 mg per 5 mL **Oral > Solid > dispersible tablet:** 50 mg **Oral > Solid > tablet:** 200 mg (EML)
Historique des statuts LME	Ajouté pour la première fois en 1999 (TRS 895) Modifié en 2002 (TRS 914) Modifié en 2007 (TRS 950) Modifié en 2015 (TRS 994) Modifié en 2023 (TRS 1049)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Limite d'âge	> 6 weeks
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Wikipédia	Nevirapine
DrugBank	Nevirapine

Résumé des preuves et recommandation du comité d'experts

The Expert Committee recommended addition of nevirapine 50 mg dispersible tablet formulation to the core list of the EML and EMLc for the treatment of children and adolescents with HIV-1 infection. The Expert Committee agreed on the public health need for paediatric formulations of ART medicines and considered that the proposed formulation of nevirapine represented a rational treatment option for paediatric HIV patients. The Committee noted that this formulation is included in the 2013 WHO guidelines and are categorized by the IATT as an“optimal” paediatric formulation.